513 related articles for article (PubMed ID: 29980239)
21. Co-expression of IL-4/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment.
Zhou Y; Farooq MA; Ajmal I; He C; Gao Y; Guo D; Duan Y; Jiang W
Biomed Pharmacother; 2023 Dec; 168():115740. PubMed ID: 37865999
[TBL] [Abstract][Full Text] [Related]
22. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.
Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S
Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627
[TBL] [Abstract][Full Text] [Related]
23. CAR T-cell therapy for triple-negative breast cancer: Where we are.
Xie Y; Hu Y; Zhou N; Yao C; Wu L; Liu L; Chen F
Cancer Lett; 2020 Oct; 491():121-131. PubMed ID: 32795486
[TBL] [Abstract][Full Text] [Related]
24. EGFR as a potent CAR T target in triple negative breast cancer brain metastases.
Subham S; Jeppson JD; Worcester C; Schatmeyer B; Zhao J; Madan R; Lakis NS; Kimler BF; McGuirk JP; Chen RC; Stecklein SR; Akhavan D
Breast Cancer Res Treat; 2023 Jan; 197(1):57-69. PubMed ID: 36318382
[TBL] [Abstract][Full Text] [Related]
25. T cells with split CARs specific for NKG2D ligands and PD-L1 exhibit improved selectivity towards monocyte-derived cells while effective in eliminating acute myeloid leukaemia in vivo.
Sun L; Jiang G; Ng YY; Xiao L; Du Z; Wang S; Zhu J
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10189-10201. PubMed ID: 37270461
[TBL] [Abstract][Full Text] [Related]
26. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).
Song DG; Ye Q; Carpenito C; Poussin M; Wang LP; Ji C; Figini M; June CH; Coukos G; Powell DJ
Cancer Res; 2011 Jul; 71(13):4617-27. PubMed ID: 21546571
[TBL] [Abstract][Full Text] [Related]
27. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
28. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
Lazarova M; Wels WS; Steinle A
Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
[TBL] [Abstract][Full Text] [Related]
29. Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer.
Raftery MJ; Franzén AS; Radecke C; Boulifa A; Schönrich G; Stintzing S; Blohmer JU; Pecher G
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240385
[TBL] [Abstract][Full Text] [Related]
30. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
Ding H; Yang X; Wei Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
[TBL] [Abstract][Full Text] [Related]
31. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
32. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
Song DG; Ye Q; Poussin M; Harms GM; Figini M; Powell DJ
Blood; 2012 Jan; 119(3):696-706. PubMed ID: 22117050
[TBL] [Abstract][Full Text] [Related]
33. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
[TBL] [Abstract][Full Text] [Related]
34. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Baumeister SH; Murad J; Werner L; Daley H; Trebeden-Negre H; Gicobi JK; Schmucker A; Reder J; Sentman CL; Gilham DE; Lehmann FF; Galinsky I; DiPietro H; Cummings K; Munshi NC; Stone RM; Neuberg DS; Soiffer R; Dranoff G; Ritz J; Nikiforow S
Cancer Immunol Res; 2019 Jan; 7(1):100-112. PubMed ID: 30396908
[TBL] [Abstract][Full Text] [Related]
35. Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis.
Jiang G; Ng YY; Tay JCK; Du Z; Xiao L; Wang S; Zhu J
Cancer Immunol Immunother; 2023 Jan; 72(1):223-234. PubMed ID: 35809118
[TBL] [Abstract][Full Text] [Related]
36. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
[TBL] [Abstract][Full Text] [Related]
37. Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy.
Zaib T; Cheng K; Liu T; Mei R; Liu Q; Zhou X; He L; Rashid H; Xie Q; Khan H; Xu Y; Sun P; Wu J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768478
[TBL] [Abstract][Full Text] [Related]
38. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
Spear P; Barber A; Rynda-Apple A; Sentman CL
Immunol Cell Biol; 2013 Jul; 91(6):435-40. PubMed ID: 23628805
[TBL] [Abstract][Full Text] [Related]
39. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
[TBL] [Abstract][Full Text] [Related]
40. Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer.
Zhang Y; Li X; Zhang J; Mao L
Biomed Pharmacother; 2020 Nov; 131():110562. PubMed ID: 32920508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]